{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"7"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"14"},{"groupId":"OG011","value":"5"}]}],"title":"Leukopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"62"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"8"},{"groupId":"OG011","value":"6"}]}],"title":"Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"16"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"13"},{"groupId":"OG009","value":"22"},{"groupId":"OG010","value":"20"},{"groupId":"OG011","value":"31"}]}],"title":"Lymphopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"1"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"2"}]}],"title":"Thrombocytopenia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"77"},{"groupId":"OG004","value":"77"},{"groupId":"OG005","value":"77"},{"groupId":"OG006","value":"76"},{"groupId":"OG007","value":"76"},{"groupId":"OG008","value":"76"},{"groupId":"OG009","value":"76"},{"groupId":"OG010","value":"76"},{"groupId":"OG011","value":"76"}],"units":"Participants"}],"description":"To describe acute hematologic, neuropathic, and infectious toxicities as they relate to transfusion requirements, growth factor support, episodes of febrile neutropenia and hospitalizations, according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.","groups":[{"description":"Participants receive AEPA regimen for 2 cycles (cycle length 28 days)\n\n(A) Brentuximab vedotin 1.2 mg/kg IV (E) Etoposide 125 mg/m\\^2 IV (P) Prednisone 60 mg/m\\^2/day PO (orally) (A) Doxorubicin 40 mg/m\\^2 IV\n\nFor those with lymph nodes that do not go into remission after 2 courses of AEPA chemotherapy, radiation therapy will be given.","id":"OG000","title":"Cycle 1 - Grade 2"},{"description":"Participants receive AEPA regimen for 2 cycles (cycle length 28 days)\n\n(A) Brentuximab vedotin 1.2 mg/kg IV (E) Etoposide 125 mg/m\\^2 IV (P) Prednisone 60 mg/m\\^2/day PO (orally) (A) Doxorubicin 40 mg/m\\^2 IV\n\nFor those with lymph nodes that do not go into remission after 2 courses of AEPA chemotherapy, radiation therapy will be given.","id":"OG001","title":"Cycle 1 - Grade 3-4"},{"description":"Participants receive AEPA regimen for 2 cycles (cycle length 28 days)\n\n(A) Brentuximab vedotin 1.2 mg/kg IV (E) Etoposide 125 mg/m\\^2 IV (P) Prednisone 60 mg/m\\^2/day PO (orally) (A) Doxorubicin 40 mg/m\\^2 IV\n\nFor those with lymph nodes that do not go into remission after 2 courses of AEPA chemotherapy, radiation therapy will be given.","id":"OG002","title":"Cycle 2 - Grade 2"},{"description":"Participants receive AEPA regimen for 2 cycles (cycle length 28 days)\n\n(A) Brentuximab vedotin 1.2 mg/kg IV (E) Etoposide 125 mg/m\\^2 IV (P) Prednisone 60 mg/m\\^2/day PO (orally) (A) Doxorubicin 40 mg/m\\^2 IV\n\nFor those with lymph nodes that do not go into remission after 2 courses of AEPA chemotherapy, radiation therapy will be given.","id":"OG003","title":"Cycle 2 - Grade 3-4"},{"description":"Participants receive CAPDac regimen for 4 cycles (cycle length 21 days):\n\n(C) Cyclophosphamide IV 500 mg/m\\^2 (A) Brentuximab vedotin 1.2 mg/kg IV (P) Prednisone 40 mg/40 mg/m\\^2/day PO (Dac) Dacarbazine 250 mg/m\\^2 IV","id":"OG004","title":"Cycle 3 - Grade 2"},{"description":"Participants receive CAPDac regimen for 4 cycles (cycle length 21 days):\n\n(C) Cyclophosphamide IV 500 mg/m\\^2 (A) Brentuximab vedotin 1.2 mg/kg IV (P) Prednisone 40 mg/40 mg/m\\^2/day PO (Dac) Dacarbazine 250 mg/m\\^2 IV","id":"OG005","title":"Cycle 3 - Grade 3-4"},{"description":"Participants receive CAPDac regimen for 4 cycles (cycle length 21 days):\n\n(C) Cyclophosphamide IV 500 mg/m\\^2 (A) Brentuximab vedotin 1.2 mg/kg IV (P) Prednisone 40 mg/40 mg/m\\^2/day PO (Dac) Dacarbazine 250 mg/m\\^2 IV","id":"OG006","title":"Cycle 4 - Grade 2"},{"description":"Participants receive CAPDac regimen for 4 cycles (cycle length 21 days):\n\n(C) Cyclophosphamide IV 500 mg/m\\^2 (A) Brentuximab vedotin 1.2 mg/kg IV (P) Prednisone 40 mg/40 mg/m\\^2/day PO (Dac) Dacarbazine 250 mg/m\\^2 IV","id":"OG007","title":"Cycle 4 - Grade 3-4"},{"description":"Participants receive CAPDac regimen for 4 cycles (cycle length 21 days):\n\n(C) Cyclophosphamide IV 500 mg/m\\^2 (A) Brentuximab vedotin 1.2 mg/kg IV (P) Prednisone 40 mg/40 mg/m\\^2/day PO (Dac) Dacarbazine 250 mg/m\\^2 IV","id":"OG008","title":"Cycle 5 - Grade 2"},{"description":"Participants receive CAPDac regimen for 4 cycles (cycle length 21 days):\n\n(C) Cyclophosphamide IV 500 mg/m\\^2 (A) Brentuximab vedotin 1.2 mg/kg IV (P) Prednisone 40 mg/40 mg/m\\^2/day PO (Dac) Dacarbazine 250 mg/m\\^2 IV","id":"OG009","title":"Cycle 5 - Grade 3-4"},{"description":"Participants receive CAPDac regimen for 4 cycles (cycle length 21 days):\n\n(C) Cyclophosphamide IV 500 mg/m\\^2 (A) Brentuximab vedotin 1.2 mg/kg IV (P) Prednisone 40 mg/40 mg/m\\^2/day PO (Dac) Dacarbazine 250 mg/m\\^2 IV","id":"OG010","title":"Cycle 6 - Grade 2"},{"description":"Participants receive CAPDac regimen for 4 cycles (cycle length 21 days):\n\n(C) Cyclophosphamide IV 500 mg/m\\^2 (A) Brentuximab vedotin 1.2 mg/kg IV (P) Prednisone 40 mg/40 mg/m\\^2/day PO (Dac) Dacarbazine 250 mg/m\\^2 IV","id":"OG011","title":"Cycle 6 - Grade 3-4"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Toxicities reported below for the current study (HLHR13) include all reported hematological toxicities from a participant's on-study date through end of therapy.","reportingStatus":"POSTED","timeFrame":"From enrollment to end of therapy (approximately 8 months)","title":"Descriptive of Hematological Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}